ALXN:NSD-Alexion Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 182.50

Change

0.00 (0.00)%

Market Cap

USD 40.34B

Volume

3.00

Avg Analyst Target

USD 189.00 (+3.56%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.

Company Website : http://www.alexion.com

Address : 121 Seaport Boulevard, Boston, MA, United States, 02210

Employees : 3,837

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.26

52 Week High : 187.45

Short Ratio : 5.36

52 Week Low : 112.27

Shorted Shares : 9,803,110

200 Day Moving Average : 165.77

Shorted Shares Previous Month : 8,553,633

50 Day Moving Average : 182.75

Shares Held By Insiders : 0.27%

Short Percentage : 4.00%

Shares Held by Institutions : 88.02%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

 USD131.81B 38.58 31.39
BNTX BioNTech SE

N/A

 USD67.50B 15.50 10.94
REGN Regeneron Pharmaceuticals Inc

N/A

 USD61.22B 10.34 7.53
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD48.54B 24.20 15.87
BGNE BeiGene Ltd

N/A

 USD35.36B N/A N/A
SGEN Seagen Inc

N/A

 USD31.19B 53.49 43.63
GMAB Genmab A/S

N/A

 USD30.33B 78.11 8.55
ALNY Alnylam Pharmaceuticals Inc

N/A

 USD23.60B N/A N/A
RPRX Royalty Pharma plc

N/A

 USD22.77B 30.36 12.47
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ALXN

Symbol Name Weight Mer Price(Change) Market Cap
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

 USD9.12M
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

N/A

 USD0.06B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

 USD0.02B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

 USD2.51M
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

 USD0.03B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

 USD0.40B
ETLI:XETRA Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

 USD0.04B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.81% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.81% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 50.07% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.07% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 50.07% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.07% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.90% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.90% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.06% N/A N/A N/A N/A
Risk Adjusted Return 32.94% N/A N/A N/A N/A
Market Capitalization 40.34B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 59.23 N/A N/A N/A N/A
Price/Book Ratio 3.25 N/A N/A N/A N/A
Price / Cash Flow Ratio 13.43 N/A N/A N/A N/A
EV/EBITDA 42.56 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 4.43% N/A N/A N/A N/A
Return on Invested Capital 20.68% N/A N/A N/A N/A
Return on Assets 10.08% N/A N/A N/A N/A
Debt to Equity Ratio 20.77% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.36 N/A N/A N/A N/A
Short Percent 4.44% N/A N/A N/A N/A
Beta 1.26 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike